The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, answers the question: How should we treat smoldering myeloma?
Professor (Prof.) Ghobrial discusses the often debated topic of whether we should or should not treat smoldering multiple myeloma (SMM). Prof. Ghobrial argues in favor of treating SMM, but highlights it is important to select the right patients for treatment to avoid over-treatment. Additionally, Prof. Ghobrial discusses new options for treating SMM as presented during the ASH meeting such as daratumumab monotherapy for low-risk SMM, and different approaches using biomarkers and cytogenetic information.